# A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

> **NCT04116541** · PHASE2 · RECRUITING · sponsor: **Centre Leon Berard** · enrollment: 455 (estimated)

## Conditions studied

- Malignant Solid Tumor

## Interventions

- **DRUG:** HDM201
- **DRUG:** Ribociclib
- **DRUG:** Cabozantinib
- **DRUG:** Alectinib
- **DRUG:** Regorafenib
- **DRUG:** Trametinib
- **DRUG:** Dabrafenib
- **DRUG:** Avapritinib

## Key facts

- **NCT ID:** NCT04116541
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-01-28
- **Primary completion:** 2026-10
- **Final completion:** 2027-10
- **Target enrollment:** 455 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04116541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04116541, "A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04116541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*